CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
Masimo to Present in the Jefferies London Healthcare Conference
Masimo (NASDAQ: MASI) today announced that its management will participate in the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:30 a.m. GMT. A live webcast of the presentation will be available on the Masimo website at A replay of the webcast will be available following the live presentation.
Merck to Participate in the Jefferies London Healthcare Conference
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, and Dr. Marjorie Green, senior vice president and head of oncology,
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar,
Korro to Present at the Jefferies London Healthcare Conference
Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to affect a precise yet transient single base edit.
Aurinia to Participate in Jefferies London Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the Jefferies Healthcare Conference in London, November 19-21, 2024.
Hosted on MSN14d
Is CRISPR Therapeutics (CRSP) a Promising Gene Editing Stock?
In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other most promising gene editing stocks to buy according to hedge funds. The pharmaceutical ...
Zacks.com on MSN8d
Wall Street Analysts See a 62.75% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?
Shares of CRISPR Therapeutics AG (CRSP) have gained 11.4% over the past four weeks to close the last trading session at $50.36, but there could still be a solid upside left in the stock if short-term ...
CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates
CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.
ETF Daily News3d
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $74.94 Consensus Price Target from Analysts
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been given an average recommendation of “Hold” by the nineteen brokerages that are covering the company, Marketbeat Ratings reports. Two ...
Crispr Therapeutics AG: Buy Rating Affirmed Amid Pipeline Progress and Strategic Collaborations
Leerink Partners analyst Mani Foroohar maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) on November 5 and set a ...
news.stocktradersdaily14d
(CRSP) Long Term Investment Analysis
Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP.
Morningstar2d
CRISPR Therapeutics AG CRSP
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Wall Street Journal1d
CRSP US Mid Cap Index
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...